Hyperion DeFi (NASDAQ:HYPD) Price Target Raised to $7.10

Hyperion DeFi (NASDAQ:HYPD) had its target price boosted by Cantor Fitzgerald from $6.60 to $7.10 in a research report issued on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 163.94% from the stock’s previous close.

Several other equities research analysts also recently issued reports on HYPD. Chardan Capital reiterated a “buy” rating and issued a $7.30 target price on shares of Hyperion DeFi in a research note on Tuesday. Weiss Ratings upgraded Hyperion DeFi from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, June 24th. Finally, Zacks Research raised Hyperion DeFi from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 14th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $7.20.

Hyperion DeFi Price Performance

Shares of HYPD opened at $2.69 on Thursday. The company has a current ratio of 1.97, a quick ratio of 1.97 and a debt-to-equity ratio of 0.12. The company’s fifty day simple moving average is $2.92 and its 200 day simple moving average is $3.36. Hyperion DeFi has a 1-year low of $2.34 and a 1-year high of $15.00. The company has a market cap of $40.78 million, a price-to-earnings ratio of -0.27 and a beta of 2.53.

Hyperion DeFi (NASDAQ:HYPD) last announced its quarterly earnings data on Thursday, August 13th. The company reported $0.92 EPS for the quarter. The firm had revenue of $0.36 million during the quarter. On average, research analysts forecast that Hyperion DeFi will post 1.71 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Hyunsu Jung bought 7,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was bought at an average price of $3.70 per share, for a total transaction of $25,900.00. Following the purchase, the insider owned 1,384,676 shares in the company, valued at $5,123,301.20. This represents a 0.51% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 7.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Redwood Wealth Management Group LLC increased its position in Hyperion DeFi by 2.1% during the 1st quarter. Redwood Wealth Management Group LLC now owns 183,273 shares of the company’s stock worth $632,000 after buying an additional 3,690 shares during the period. Sanctuary Advisors LLC acquired a new position in shares of Hyperion DeFi during the 4th quarter worth approximately $38,000. Nations Financial Group Inc. IA ADV bought a new position in shares of Hyperion DeFi during the fourth quarter worth approximately $40,000. Price T Rowe Associates Inc. MD acquired a new stake in shares of Hyperion DeFi in the fourth quarter valued at approximately $73,000. Finally, State Street Corp acquired a new stake in shares of Hyperion DeFi in the fourth quarter valued at approximately $92,000. 25.84% of the stock is owned by institutional investors.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.